DOCSLIB.ORG

Endogenous Prostaglandin Endoperoxides and Prostacyclin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Endogenous Prostaglandin Endoperoxides and Prostacyclin Endogenous Prostaglandin Endoperoxides and Prostacyclin Modulate the Thrombolytic Activity of Tissue Plasminogen Activator Effects of Simultaneous Inhibition of Thromboxane A2 Synthase and Blockade of Thromboxane A2/Prostaglandin H2 Receptors in a Canine Model of Coronary Thrombosis Paolo Golino, Mark Rosolowsky, Sheng-Kun Yao, Janice McNatt, Fred De Clerck, L. Maximilian Buja, and James T. Willerson The Texas Heart Institute and the Department ofInternal Medicine and Pathology, The University of Texas Health Science Center at Houston 77225, and the University of Texas Southwestern Medical Center at Dallas, Texas 75235 Abstract R 68070 and dazoxiben prevented the increase in plasma TxB2 levels, whereas 6-keto-PGFI. levels were significantly in- We tested the hypothesis that simultaneous inhibition of TxA2 creased with respect to control and SQ 29548-treated dogs. synthase and blockade of TxA2/PHG2 receptors is more effec- Thus, simultaneous inhibition of TxA2 synthase and blockade tive in enhancing thrombolysis and preventing reocclusion of TxA2/PGH2 receptors is more effective than either inter- after discontinuation of tissue plasminogen activator (t-PA) vention alone in this experimental model in enhancing throm- than either intervention alone. Coronary thrombosis was in- bolysis and preventing reocclusion after t-PA administration. duced in 35 dogs by placing a copper coil into the left anterior (J. Clin. Invest. 1990. 86:1095-1102.) Key words: thromboly- descending coronary artery. Coronary flow was measured with sis * tissue plasminogen activator - prostaglandin endoperox- a Doppler flow probe. 30 min after thrombus formation, the ides * thromboxane A2 synthase inhibitors * thromboxane A2 animals received saline (controls, n = 10); SQ 29548 (0.4 receptor antagonists mg/kg bolus + 0.4 mg/kg per h infusion), a TxA2/PGH2 re- ceptor antagonist (n = 8); dazoxiben (5 mg/kg bolus + 5 Introduction mg/kg per h infusion), a TxA2 synthase inhibitor (n = 9); or R Early thrombolysis is now considered the treatment of choice 68070 (5 mg/kg bolus + 5 mg/kg per h infusion), a drug that for many patients with acute myocardial infarction. Attention blocks TxA2/PGH2 receptors and inhibits TxA2 synthase (n has been focused on thrombolytic agents with a more pro- = 8). Then, all dogs received heparin (200 U/kg) and a bolus of nounced thrombus selectivity, such as tissue-type plasminogen t-PA (80 ;&g/kg) followed by a continuous infusion (8 ag/kg per activator (t-PA).' t-PA offers the advantage of resulting in min) for up to 90 min or until reperfusion was achieved. The comparable reperfusion rates when given intravenously as time to thrombolysis did not change significantly in SQ compared with the intracoronary administration of strepto- 29548-treated dogs as compared with controls (42 ± 5 vs. 56 kinase and to cause less extensive systemic fibrinogenolysis ± 7 min, respectively, P = NS), but it was significantly short- (1-7). However, despite these advantages of t-PA over strepto- ened by R 68070 and dazoxiben (11 ± 2 and 25 ± 6 min, kinase, some problems with t-PA as a thrombolytic agent re- respectively, P < 0.001 vs. controls and SQ 29548-treated main. First, the incidence of reperfusion varies between 60 and dogs). R 68070 administration resulted in a lysis time signifi- 80% of patients (1-7). Second, the time necessary to achieve cantly shorter than that observed in the dazoxiben-treated reperfusion from the beginning of t-PA administration is often group (P < 0.01). Reocclusion was observed in eight of eight at least 45 min (1-7). Finally, a substantial incidence of reoc- control dogs, five of seven SQ 29548-treated dogs, seven of clusion, which exists after the adminstration of t-PA, is dis- nine dazoxiben-treated dogs, and zero of eight R 68070-treated continued despite the use of heparin (1-7). Thus, substantial animals (P < 0.001). TxB2 and 6-keto-PGFia, measured in effort is being made to develop better thrombolytic agents blood samples obtained from the coronary artery distal to the and/or adjunctive therapies to be used in conjunction with thrombus, were significantly increased at reperfusion and at currently available thrombolytic agents. reocclusion in control animals and in dogs receiving SQ 29548. We (8) and others (9, 10) have demonstrated that intracor- onary platelet activation plays a major role in causing early reocclusion after discontinuation of t-PA in experimental Presented in part at the 62nd Scientific Session of the American Heart models of coronary thrombosis. Furthermore, intracoronary Association, New Orleans, LA, 1989. platelet activation and deposition on the thrombus may pro- Address correspondence and reprint requests to Dr. James T. Wil- ceed during administration of t-PA, thus increasing the total lerson, Department of Internal Medicine, The University of Texas Health Science Center at Houston, P.O. Box 20708, Houston, TX amount of thrombus to be lysed and prolonging the time to 77225. Dr. Golino's present address is Clinica Medica I, Cattedra di reperfusion. We have shown that TxA2 and serotonin coopera- Cardiologia, II Facolta' di Medicina, via S. Pansini 5, 80131 Napoli, tively mediate these phenomena, as TxA2 and serotonin antag- Italy. Dr. De Clerck's present address is Janssen Pharmaceuticals, onists given in combination, but not either intervention alone, Beerse, Belgium. markedly shorten the time to reperfusion and prevent or delay Receivedfor publication 23 February 1990 and in revisedform 17 reocclusion after discontinuation of t-PA (11). May 1990. TxA2, the major product of arachidonic acid metabolism J. Clin. Invest. © The American Society for Clinical Investigation, Inc. 1. Abbreviations used in this paper: ACT, activated coagulation time; 0021-9738/90/10/1095/08 $2.00 LAD; left anterior descending coronary artery; t-PA, tissue plasmino- Volume 86, October 1990, 1095-1102 gen activator. Modulation oft-PA Activity by Endogenous Prostaglandins 1095 in platelets, is a potent platelet agonist and vasoconstrictor ence of the intracoronary thrombus was documented for 30 min. The (12), and contributes in the pathophysiology of certain acute animals were then randomly assigned to one of the following groups: a coronary artery disease syndromes (13). One way to overcome group receiving saline (group I, n = 10) served as control; a group the deleterious effects of TxA2 is by inhibiting TxA2 synthase, received a bolus of SQ 29548 (0.4 mg/kg), a potent and selective the enzyme responsible for the conversion of PG endoperox- TxA2/PGH2 receptor antagonist (Squibb Pharmaceuticals, Princeton, NJ) (21, 22), followed by a continuous infusion (0.4 mg/kg per h) ides (PGG2/PGH2) to TxA2 (14). This approach has the ad- (group II, n = 8); a third group received a bolus ofdazoxiben (5 mg/kg), vantage over cyclooxygenase inhibition of leaving the biosyn- a selective TxA2 synthase inhibitor (Pfizer Pharmaceuticals, Groton, thesis of prostacyclin (PGI2) intact (15). PGI2 is the major CT) (23), followed by a continuous infusion (5 mg/kg per h) (group III, product of arachidonic acid metabolism in endothelial cells, n = 9); and a fourth group received a bolus of R 68070 (5 mg/kg), a new and it is a potent anti-platelet substance ( 16). Indeed, the anti- drug with simultaneous TxA2/PGH2 receptor blocking and TxA2 syn- platelet effects of TxA2 synthase inhibitors may be potentiated thase inhibiting properties (Janssen Research Foundation, Beerse, by an increased production of anti-platelet prostaglandins Belgium) (24, 25), followed by a continuous infusion (5 mg/kg per h) formed by extra-platelet metabolism of PG endoperoxides that (group IV, n = 8). Immediately after starting drug or saline infusions, accumulate when TxA2 synthase is inhibited (17, 18). How- all dogs received a bolus of heparin (200 U/kg) and a bolus of 80 /Ag/kg ever, PG endoperoxides may also activate a receptor on plate- of recombinant human tissue-type plasminogen activator (Knoll platelet activa- Pharmaceuticals Co., Whippany, NJ) followed by an infusion of 8 let membranes, shared with TxA2, mediating Ag/kg per min for up to 90 min or until reperfusion was achieved. tion (19, 20). Thus, there may be conflicting influences as Heparin administration was eventually repeated every hour, whereas regards the anti-thrombotic activity of TxA2 synthase inhibi- R 68070, SQ 29548, or dazoxiben infusion was maintained throughout tors. Addition of a TxA2 receptor antagonist to a TxA2 syn- the study. The time necessary to achieve adequate reperfusion (defined thase inhibitor should prevent the proaggregatory effects of PG as LAD flow 2 70% of the baseline value), was identified and t-PA endoperoxides, while leaving intact the increased production infusion was discontinued at that time. of anti-platelet prostaglandins, thus resulting in a potentiation Hemodynamics and LAD blood flow velocity were monitored of antithrombotic activity. continuously until a persistent reocclusion occurred (defined as a To determine whether these mechanisms might affect the reocclusion lasting for at least 30 min) or until 90 min of total reperfu- thrombolytic activity of t-PA and the incidence of reocclusion sion time. Prostaglandin measurements. To assess the effects of drug treat- after thrombolysis, we compared the effects of simultaneous ments on intracoronary PG production, TxB2, the stable metabolite of inhibition of TxA2 synthase and blockade of TxA2/PGH2 re- TxA2, and 6-keto-PGFIa, the stable metabolite of PGI2, were mea- ceptors on lysis time and incidence of reocclusion in a canine sured in blood samples obtained from the distal coronary catheter. model of coronary thrombosis. This study provides direct evi- Blood samples were taken before placement of the copper coil into the dence that this approach is more effective than either inter- LAD 1 min after reperfusion was achieved, and at the moment of vention alone in this model, and suggests a new class of agents reocclusion or after 90 min of reperfusion. When a persistent reocclu- with potential therapeutic importance during coronary throm- sion occurred, LAD blood flow approached zero and flow from the bosis and thrombolysis.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • Role of Proaggregatory and Antiaggregatory Prostaglandins in Hemostasis
    Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. P Gresele, … , G Pieters, J Vermylen J Clin Invest. 1987;80(5):1435-1445. https://doi.org/10.1172/JCI113223. Research Article Thromboxane synthase inhibition can lead to two opposing effects: accumulation of proaggregatory cyclic endoperoxides and increased formation of antiaggregatory PGI2 and PGD2. The elimination of the effects of the cyclic endoperoxides by an endoperoxide-thromboxane A2 receptor antagonist should enhance the inhibition of hemostasis by thromboxane synthase blockers. We have carried out a series of double-blind, placebo-controlled, crossover studies in healthy volunteers to check if this hypothesis may be operative in vivo in man. In a first study, in 10 healthy male volunteers, the combined administration of the thromboxane receptor antagonist BM 13.177 and the thromboxane synthase inhibitor dazoxiben gave stronger inhibition of platelet aggregation and prolonged the bleeding time more than either drug alone. In a second study, in 10 different healthy male volunteers, complete inhibition of cyclooxygenase with indomethacin reduced the prolongation of the bleeding time by the combination BM 13.177 plus dazoxiben. In a third study, in five volunteers, selective cumulative inhibition of platelet TXA2 synthesis by low-dose aspirin inhibited platelet aggregation and prolonged the bleeding time less than the combination BM 13.177 plus dazoxiben. In vitro, in
    [Show full text]
  • Effect of Prostanoids on Human Platelet Function: an Overview
    International Journal of Molecular Sciences Review Effect of Prostanoids on Human Platelet Function: An Overview Steffen Braune, Jan-Heiner Küpper and Friedrich Jung * Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology, 01968 Senftenberg, Germany; steff[email protected] (S.B.); [email protected] (J.-H.K.) * Correspondence: [email protected] Received: 23 October 2020; Accepted: 23 November 2020; Published: 27 November 2020 Abstract: Prostanoids are bioactive lipid mediators and take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. In this review, we focus on their influence on platelets, which are key elements in thrombosis and hemostasis. The function of platelets is influenced by mediators in the blood and the vascular wall. Activated platelets aggregate and release bioactive substances, thereby activating further neighbored platelets, which finally can lead to the formation of thrombi. Prostanoids regulate the function of blood platelets by both activating or inhibiting and so are involved in hemostasis. Each prostanoid has a unique activity profile and, thus, a specific profile of action. This article reviews the effects of the following prostanoids: prostaglandin-D2 (PGD2), prostaglandin-E1, -E2 and E3 (PGE1, PGE2, PGE3), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane-A2 (TXA2) on platelet activation and aggregation via their respective receptors. Keywords: prostacyclin; thromboxane; prostaglandin; platelets 1. Introduction Hemostasis is a complex process that requires the interplay of multiple physiological pathways. Cellular and molecular mechanisms interact to stop bleedings of injured blood vessels or to seal denuded sub-endothelium with localized clot formation (Figure1).
    [Show full text]
  • Acute Necrotizing Pancreatitis in Rats
    ACUTE NECROTIZING PANCREATITIS IN RATS Acute necrotizerende pancreatitis in ratten PROEFSCHRIFT TER VERKRIJGING VAN DE GRAAD VAN DOCTOR IN DE GENEESKUNDE AAN DE ERASMUS UNIVERSITEIT ROTTERDAM OP GEZAG VAN DE RECTOR MAGNIFICUS PROF. DR. A.H.G. RINNOOY KAN EN VOLGENS BESLUIT VAN HET COLLEGE VAN DEKANEN. DE OPENBARE VERDEDIGING ZAL PLAATSVINDEN OP VRIJDAG 22 JANUARI 1988 TE 15.45 UUR door BAAN VAN OOIJEN geboren te Rotterdam Druk: Krips Repro Meppel 1987 PROMOTIECOMMISSIE PROMOTOREN PROF. J.H.P. WILSON PROF. DR. J. JEEKEL OVERIGE LEDEN: PROF. DR. I.L. BONTA PROF. DR. J.L. TERPSTRA 1987 B. van Ooijen No part of this book may be reproduced in any form, by print, photoprint, microfilm or any other means without written permission from the publisher. De druk van dit proefschrift werd mede mogelijk gemaakt door financiele steun van het Bronovo Researchfonds. Wat heb ik dat ik niet gekregen heb? aJNTENTS page ABBREVIATIONS CHAPTER 1: INTRODUCTION AND AIM OF THE STUDY. 1 1.1. References 3 CHAPTH• 2: ETIOLOGICAL FACTORS IN ACUTE PANCREATITIS. 2. 1. Introduction 4 2.2. Etiological factors 5 2.2.1. Mechanical block at ampulla 6 a. Biliary tract disease 6 a-1. Bile reflux 7 a-2. Pancreatic duct obstruction 8 b. Obstruction at the level of the ampulla 8 b-1. Pancreas divisum 9 c. Duodenal disorders 9 2.2.2. Vascular factors and ischemia 9 2.2.3. Toxic and metabolic factors 10 a. Alcoholism 10 b. Hypercalcemia 11 c. Hypertriglyceridemia 12 d. Other metabolic causes 12 e. Drugs 12 2.2.4. Infection 13 2.2.5.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0286160 A1 Gilbert Et Al
    US 2010O286160A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0286160 A1 Gilbert et al. (43) Pub. Date: Nov. 11, 2010 (54) SUBSTITUTED PIPERAZINES AS CB1 Related U.S. Application Data ANTAGONSTS (60) Provisional application No. 60/946,896, filed on Jun. (75) Inventors: Eric J. Gilbert, Scotch Plains, NJ 28, 2007. (US); William J. Greenlee, Teaneck, NJ (US); Sarah Wei Li, Publication Classification Belle Mead, NJ (US); Michael W. (51) Int. Cl. Miller, Scotch Plains, NJ (US); A 6LX 3L/2197 (2006.01) Jack D. Scott, Scotch Plains, NJ C07D 24I/04 (2006.01) (US); Adrew Stamford, Chatham C07D 403/2 (2006.01) Township, NJ (US); Chander C07D 24I/02 (2006.01) Shekher Celly, Colonia, NJ (US) C07D 40/12 (2006.01) C07D 40/4 (2006.01) Correspondence Address: A6IP 9/00 (2006.01) MERCK PATENT DEPARTMENT (K-6-1, 1990) (52) U.S. Cl. .................... 514/252.11:544/400: 544/372: 2000 GALLOPNGHILL ROAD 544/370; 544/357: 514/254.01: 514/254.05; KENILWORTH, NJ 07033-0530 (US) 514/252.12:544/360; 514/253.13:544/364; 514/253.09 (73) Assignee: Intervet Inc. (57) ABSTRACT (21) Appl. No.: 12/665,253 Compounds of Formula (I): or pharmaceutically acceptable (22) PCT Fled: Jun. 25, 2008 salts, Solvates, oresters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic (86) PCT NO.: PCT/US08/07917 syndrome and obesity, neuroinflammatory disorders, cogni tive disorders and psychosis, addiction (e.g., Smoking cessa S371 (c)(1), tion), gastrointestinal disorders, and cardiovascular condi (2), (4) Date: Jun.
    [Show full text]
  • Patent Application Publication (10) Pub. No.: US 2009/0131395 A1 Antonelli Et Al
    US 20090131395A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0131395 A1 Antonelli et al. (43) Pub. Date: May 21, 2009 (54) BIPHENYLAZETIDINONE CHOLESTEROL Publication Classification ABSORPTION INHIBITORS (51) Int. Cl. (75) Inventors: Stephen Antonelli, Lynn, MA A 6LX 3L/397 (2006.01) (US); Regina Lundrigan, C07D 205/08 (2006.01) Charlestown, MA (US); Eduardo J. A6IP 9/10 (2006.01) Martinez, St. Louis, MO (US); Wayne C. Schairer, Westboro, MA (52) U.S. Cl. .................................... 514/210.02:540/360 (US); John J. Talley, Somerville, MA (US); Timothy C. Barden, Salem, MA (US); Jing Jing Yang, (57) ABSTRACT Boxborough, MA (US); Daniel P. The invention relates to a chemical genus of 4-biphenyl-1- Zimmer, Somerville, MA (US) phenylaZetidin-2-ones useful in the treatment of hypercho Correspondence Address: lesterolemia and other disorders. The compounds have the HESLN ROTHENBERG EARLEY & MEST general formula I: PC S COLUMBIA. CIRCLE ALBANY, NY 12203 (US) (73) Assignee: MICROBIA, INC., Cambridge, MA (US) “O O (21) Appl. No.: 11/913,461 o R2 R4 X (22) PCT Filed: May 5, 2006 R \ / (86). PCT No.: PCT/USO6/17412 S371 (c)(1), (2), (4) Date: May 30, 2008 * / Related U.S. Application Data (60) Provisional application No. 60/677,976, filed on May Pharmaceutical compositions and methods for treating cho 5, 2005. lesterol- and lipid-associated diseases are also disclosed. US 2009/013 1395 A1 May 21, 2009 BPHENYLAZETIONONE CHOLESTEROL autoimmune disorders, (6) an agent used to treat demylena ABSORPTION INHIBITORS tion and its associated disorders, (7) an agent used to treat Alzheimer's disease, (8) a blood modifier, (9) a hormone FIELD OF THE INVENTION replacement agent/composition, (10) a chemotherapeutic 0001.
    [Show full text]
  • Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs
    DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 DMD FastThis Forward. article has not Published been copyedited on andSeptember formatted. The 7, final 2012 version as doi:10.1124/dmd.112.047068may differ from this version. DMD #47968 Mitigating the inhibition of human Bile Salt Export Pump by drugs: opportunities provided by physicochemical property modulation, in-silico modeling and structural modification Daniel J. Warner, Hongming Chen, Louis-David Cantin, J. Gerry Kenna, Simone Stahl, Clare L. Walker, Tobias Noeske. Department of Medicinal Chemistry, AstraZeneca R&D Montreal, Montreal, Quebec, H4S Downloaded from 1Z9, Canada (DJW, LDC) Computational Sciences, Discovery Sciences, AstraZeneca R&D Mölndal, Pepparedsleden dmd.aspetjournals.org 1, Mölndal 43183, Sweden (HC) Molecular Toxicology, Global Safety Assessment, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK (JGK, SS, CLW) Global Safety Assessment, AstraZeneca R&D Mölndal, Pepparedsleden 1, Mölndal 43183, at ASPET Journals on October 10, 2021 Sweden (TN) 1 Copyright 2012 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 This article has not been copyedited and formatted. The final version may differ from this version. DMD #47968 Inhibition of the human Bile Salt Export Pump by drugs. Corresponding author: Tobias Noeske Global Safety Assessment AstraZeneca R&D Mölndal S-431 83 Mölndal, Sweden Phone: +46-31-7064002 Mobile: +46-727-158344
    [Show full text]
  • Effects of Platelet-Modifying Drugs on Arterial Thromboembolism in Baboons
    Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. S R Hanson, … , L A Harker, T D Bjornsson J Clin Invest. 1985;75(5):1591-1599. https://doi.org/10.1172/JCI111865. Research Article To resolve questions of drug actions, efficacy, and interactions for platelet-modifying agents used clinically, we have compared the relative capacities and mechanisms of aspirin, dipyridamole, sulfinpyrazone, and dazoxiben to prevent arterial thromboembolism in a baboon model. In 136 studies the agents were given twice daily by oral administration both singly and in combination. The antithrombotic efficacy of a given therapy was determined by its capacity to interrupt steady-state platelet utilization induced by thrombogenic arteriovenous cannulae. When given alone, dipyridamole and sulfinpyrazone reduced the rate at which platelets were utilized by thrombus formation in a dose-dependent manner with essentially complete interruption by dipyridamole at 10 mg/kg per d. In contrast, neither aspirin (2-100 mg/kg per d) nor dazoxiben (20-100 mg/kg per d) decreased cannula platelet consumption detectably despite the striking reduction in the capacity of platelets to produce thromboxane B2. However, aspirin, but not dazoxiben, potentiated the antithrombotic effects of dipyridamole and sulfinpyrazone in a dose-dependent fashion without changing the pharmacokinetics for any of the agents. Complete
    [Show full text]